Trials / Unknown
UnknownNCT05685524
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
Development of Diagnostic Model for Multi-cancer Diagnosis Based on DNA Methylation Biomarkers
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR. Meanwhile, we expect to identify several plasma methylation markers that can be highly sensitive for multi-cancer detection. Finally, we will provide a pan-cancer blood test that is easy to operate, low cost, accurate and easy to promote.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | DNA methylation test | Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform. |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-08-01
- Completion
- 2023-12-01
- First posted
- 2023-01-17
- Last updated
- 2023-01-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05685524. Inclusion in this directory is not an endorsement.